Distribuzione geografica
Continente #
NA - Nord America 10.436
EU - Europa 9.609
AS - Asia 3.698
Continente sconosciuto - Info sul continente non disponibili 30
OC - Oceania 30
SA - Sud America 30
AF - Africa 7
Totale 23.840
Nazione #
US - Stati Uniti d'America 10.406
GB - Regno Unito 4.412
CN - Cina 3.087
IE - Irlanda 959
SE - Svezia 924
FR - Francia 900
IT - Italia 773
DE - Germania 705
FI - Finlandia 586
SG - Singapore 251
UA - Ucraina 150
VN - Vietnam 141
BE - Belgio 53
KR - Corea 51
JP - Giappone 37
NL - Olanda 36
TR - Turchia 30
EU - Europa 27
RU - Federazione Russa 27
AU - Australia 24
CA - Canada 23
IN - India 22
IR - Iran 21
CL - Cile 14
AT - Austria 13
CH - Svizzera 13
HK - Hong Kong 8
PL - Polonia 8
BR - Brasile 7
SA - Arabia Saudita 7
AZ - Azerbaigian 6
NZ - Nuova Zelanda 6
RO - Romania 6
BG - Bulgaria 5
PE - Perù 5
CZ - Repubblica Ceca 4
EE - Estonia 4
GR - Grecia 4
LK - Sri Lanka 4
LV - Lettonia 4
MK - Macedonia 4
MX - Messico 4
PH - Filippine 4
UZ - Uzbekistan 4
BD - Bangladesh 3
ES - Italia 3
HU - Ungheria 3
ID - Indonesia 3
IL - Israele 3
MY - Malesia 3
NO - Norvegia 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AE - Emirati Arabi Uniti 2
AM - Armenia 2
CM - Camerun 2
CR - Costa Rica 2
DK - Danimarca 2
EC - Ecuador 2
LU - Lussemburgo 2
MA - Marocco 2
PT - Portogallo 2
SK - Slovacchia (Repubblica Slovacca) 2
TH - Thailandia 2
A1 - Anonimo 1
AL - Albania 1
BO - Bolivia 1
BY - Bielorussia 1
CO - Colombia 1
EG - Egitto 1
JO - Giordania 1
KG - Kirghizistan 1
KH - Cambogia 1
KW - Kuwait 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
PA - Panama 1
TN - Tunisia 1
TW - Taiwan 1
ZA - Sudafrica 1
Totale 23.840
Città #
Southend 4.196
Chandler 1.857
Jacksonville 1.438
Woodbridge 1.417
Ann Arbor 1.008
Dublin 958
Houston 593
Beijing 574
Ashburn 509
Lawrence 397
Princeton 397
Wilmington 377
Jinan 318
Nanjing 276
Shenyang 262
Verona 208
Hebei 169
Singapore 156
New York 155
Tianjin 155
Changsha 123
Nanchang 101
Haikou 93
Zhengzhou 93
Ningbo 87
Sindelfingen 83
Hangzhou 79
Dong Ket 78
Helsinki 76
Jiaxing 74
Milan 69
Guangzhou 61
Taizhou 59
Redwood City 58
Norwalk 54
Taiyuan 54
Brussels 53
Boardman 47
Seoul 45
Lanzhou 43
Seattle 39
Lancaster 38
Bologna 36
Fuzhou 36
Falls Church 34
Dearborn 32
San Francisco 30
Los Angeles 29
Redmond 29
Kent 28
Tokyo 28
Chicago 26
Dongguan 26
Washington 21
Düsseldorf 19
Fairfield 18
Augusta 17
Clearwater 17
Rome 13
Toronto 13
San Mateo 12
Melbourne 10
Detroit 9
Groningen 9
San Diego 9
Auburn Hills 8
Nürnberg 8
Vienna 8
Amsterdam 7
Ardabil 7
Canberra 7
Renton 7
Riva 7
Baku 6
Kochi 6
Padova 6
Sydney 6
Fremont 5
Leawood 5
Lima 5
London 5
Markgröningen 5
Paris 5
Qingdao 5
Tappahannock 5
Yicheng 5
Zanjan 5
Bari 4
Brugnera 4
Catanzaro 4
Colombo 4
Duncan 4
Florence 4
Frankfurt am Main 4
Lille 4
Prague 4
Riyadh 4
Shanghai 4
Sofia 4
Stockholm 4
Totale 17.613
Nome #
An FGFR3 autocrine loop sustains acquired resistance to trastuzumab in gastric cancer patients 198
Whole-genome landscape of pancreatic neuroendocrine tumours 158
True 3q Chromosomal Amplification in Squamous Cell Lung Carcinoma by FISH and aCGH Molecular Analysis: Impact on Targeted Drugs 145
Combined inhibition of IL1, CXCR1/2, and TGFβ signaling pathways modulates in-vivo resistance to anti-VEGF treatment 140
BRCA somatic and germline mutation detection in paraffin embedded ovarian cancers by next-generation sequencing 134
High-throughput mutation profiling identifies novel molecular dysregulation in high-grade intraepithelial neoplasia and early gastric cancers 130
A clinical-biological risk stratification model for resected gastric cancer: prognostic impact of Her2, Fhit, and APC expression status 130
A circulating TH2 cytokines profile predicts survival in patients with resectable pancreatic adenocarcinoma 128
Ampulla of Vater Carcinoma: Sequencing Analysis Identifies TP53 Status as a Novel Independent Prognostic Factor and Potentially Actionable ERBB, PI3K, and WNT Pathways Gene Mutations 124
Genomic analyses identify molecular subtypes of pancreatic cancer 122
Molecular typing of lung adenocarcinoma on cytological samples using a multigene next generation sequencing panel 118
Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups 118
Reporting tumor molecular heterogeneity in histopathological diagnosis 118
Impact of neoadjuvant single or dual HER2 inhibition and chemotherapy backbone upon pathological complete response in operable and locally advanced breast cancer: Sensitivity analysis of randomized trials 117
ALK gene copy number in lung cancer: Unspecific polyploidy versus specific amplification visible as double minutes 114
Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers 113
Acquired hemophagocytic syndrome in a patient with synovial sarcoma: a case report 111
Perfusion Changes in Liver Metastases (LM) from Pancreatic Neuroendocrine Tumors (PanNETs) during Everolimus (E) Treatment: Update of Perfusion CT (P-CT) Study 106
Tumor thrombosis: a peculiar finding associated with pancreatic neuroendocrine neoplasms. A pictorial essay 106
Magnitude of PD-1, PD-L1 and T Lymphocyte Expression on Tissue from Castration-Resistant Prostate Adenocarcinoma: An Exploratory Analysis 105
Adipocytes sustain pancreatic cancer progression through a non-canonical WNT paracrine network inducing ROR2 nuclear shuttling 103
Monosomy of chromosome 17 in breast cancer during interpretation of HER2 gene amplification 103
The identification of a small but significant subset of patients still targetable with anti-HER2 inhibitors when affected by triple negative breast carcinoma 103
Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas 102
Tumor Perfusion Changes During Everolimus (E) Treatment: Preliminary Results from Perfusion-CT (P-CT) Study 102
FGFR-1 amplification in metastatic lymph-nodal and haematogenous lobular breast carcinoma. 101
True 3q Chromosomal Amplification in Squamous Cell Lung Carcinoma by FISH and aCGH Molecular Analysis: Impact on Targeted Drugs 101
Role of Combined Ga-68-DOTATOC and F-18-FDG Positron Emission Tomography/Computed Tomography in the Diagnostic Workup of Pancreas Neuroendocrine Tumors Implications for Managing Surgical Decisions 101
An overview of angiogenesis inhibitors in Phase II studies for non-small-cell lung cancer 101
HER2/neu Gene Determination in Women Screened for Breast Carcinoma: How Screening Programs Reduce the Skyrocketing Cost of Targeted Therapy 99
Neoadjuvant strategies for triple negative breast cancer: 'state-of-the-art' and future perspectives 99
The incidence and relative risk of pulmonary toxicity in patients treated with anti-PD1/PD-L1 therapy for solid tumors: a meta-analysis of current studies 99
Molecular Pathology of Pancreatic Cancer: from bench-to-bedside translation. 97
Tumor Perfusion Changes During Everolimus (E) Treatment: Preliminary Results from Perfusion-CT (P-CT) Study 97
Prognostic impact of proliferation for resected early stage 'pure' invasive lobular breast cancer: Cut-off analysis of Ki67 according to histology and clinical validation 97
Tumor seeding after percutaneous US-guided FNA of solid pancreatic neoplasms 96
Investigating BRCA Mutations: A Breakthrough in Precision Medicine of Castration-Resistant Prostate Cancer 96
Next-generation repeat-free FISH probes for DNA amplification in glioblastoma in vivo: Improving patient selection to MDM2-targeted inhibitors 96
Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma 95
Reprofiling Metastatic Samples for Chromosome 9p and 14q Aberrations as a Strategy to Overcome Tumor Heterogeneity in Clear-cell Renal Cell Carcinoma 95
Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of Ki67 assay according to histology: prognostic relevance for resected early stage 'pure' and 'mixed' lobular breast cancer 95
Prognostic impact of early nutritional support in patients affected by locally advanced and metastatic pancreatic ductal adenocarcinoma undergoing chemotherapy 95
TAK1-regulated expression of BIRC3 predicts resistance to preoperative chemoradiotherapy in oesophageal adenocarcinoma patients 94
The Tumor Entity Denominated "clear cell-papillary renal cell carcinoma" According to the WHO 2016 new Classification, have the Clinical Characters of a Renal Cell Adenoma as does Harbor a Benign Outcome 94
Corrigendum: Whole-genome landscape of pancreatic neuroendocrine tumours 94
ALK/EML4 Fusion Gene May Be Found in Pure Squamous Carcinoma of the Lung 94
Can histogram analysis of MR images predict aggressiveness in pancreatic neuroendocrine tumors? 94
Pancreatic neuroendocrine neoplasms: Magnetic resonance imaging features according to grade and stage 94
Emerging pathways and future targets for the molecular therapy of pancreatic cancer. 93
An angiopoietin-like protein 2 autocrine signaling promotes EMT during pancreatic ductal carcinogenesis 93
Adenocarcinoma of the paraurethral glands: a case report 92
Methods to identify molecular expression of mTOR pathway: a rationale approach to stratify patients affected by clear cell renal cell carcinoma for more likely response to mTOR inhibitors. 92
Homeobox B9 Mediates Resistance to Anti-VEGF Therapy in Colorectal Cancer Patients 92
Evaluation of cell-free DNA as a biomarker for pancreatic malignancies 92
Lung neuroendocrine tumours: deep sequencing of the four WHO histotypes reveals chromatin remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D 91
Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Heat Shock Protein 90 Overexpression, Ki67 Proliferative Index, and Topoisomerase II-α Co-amplification as Predictors of Pathologic Complete Response to Neoadjuvant Chemotherapy With Trastuzumab and Docetaxel 91
Pancreatic Cancer and Obesity: Molecular Mechanisms of Cell Transformation and Chemoresistance 90
Prognostic Value of Beta-Tubulin-3 and c-Myc in Muscle Invasive Urothelial Carcinoma of the Bladder 90
Current Strategies to Overcome Resistance to ALK-Inhibitor Agents 89
Profiling mTOR pathway in neuroendocrine tumors. 89
Predictive and Prognostic Role of Tumor-Infiltrating Lymphocytes for Early Breast Cancer According to Disease Subtypes: Sensitivity Analysis of Randomized Trials in Adjuvant and Neoadjuvant Setting 89
Targeting Met and VEGFR Axis in Metastatic Castration-Resistant Prostate Cancer: 'Game Over'? 89
A selective cyclooxygenase-2 inhibitor combined with the epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) ZD1839 ('Iressa') and protein kinase A antisense causes cooperative tumor growth inhibition after oral administration 88
Addressing the best treatment for non-clear cell renal cell carcinoma: A meta-analysis of randomised clinical trials comparing VEGFR-TKis versus mTORi-targeted therapies 88
R1507, the human monoclonal antibody targeting the Insulin-like Growth Factor Receptor (IGF-1R), in combination with cetuximab can reverse acquired resistance to cetuximab in pancreatic and colon cancer models 87
Perfusion CT Changes in Liver Metastases from Pancreatic Neuroendocrine Tumors During Everolimus Treatment 87
Current and developing therapies for the treatment of non-small cell lung cancer with ALK abnormalities: update and perspectives for clinical practice 87
Wide spetcrum mutational analysis of metastatic renal cell cancer: a retrospective next generation sequencing approach 87
ESGAR 2016 Book of Abstracts 87
Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft model. 86
The coming of ramucirumab in the landscape of anti-angiogenic drugs: potential clinical and translational perspectives 85
A novel modified CpG agonist of TLR-9 inhibits EGF receptor signalling and synergistically enhances antitumor activity of cetuximab and irinotecan eradicating colon cancer xenografts 84
Tubulin inhibitors in non-small cell lung cancer: looking back and forward 84
Prognostication and response assessment in liver and pancreatic tumors: The new imaging 84
Adjuvant Chemotherapy For Resected Non-Small-Cell Lung Cancer: Future Perspectives For Clinical Research 83
Organoid-Transplant Model Systems to Study the Effects of Obesity on the Pancreatic Carcinogenesis in vivo 83
The Cardiovascular Toxicity of Abiraterone and Enzalutamide in Prostate Cancer 83
Cathepsin K expression in castration-resistant prostate carcinoma: a therapeutical target for patients at risk for bone metastases 82
Angiopoietin-Like Proteins in Angiogenesis, Inflammation and Cancer 82
Preliminary results of PRINCiPe (predictors of resistance to immunotherapy with nivolumab [NIV]) study in advanced pretreated non-small cell lung cancer (APNSCLC), investigating the role of an immune genomic signature (IGS) including JAK2, JAK3, PIAS4, PTPN2, STAT3, IFNAR2 alterations 80
Angiogenesis: A target for cancer therapy. 79
Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy. 79
Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes 79
Digital Subtraction of Magnetic Resonance Images Improves Detection and Characterization of Pancreatic Neuroendocrine Neoplasms 79
Complete remission with sunitinib in a poor-risk patient with metastatic renal cell carcinoma: the fine balance between toxicity and efficacy 78
Selected news from the 2014 Genitourinary Cancers Symposium: translating novel strategies into clinical practice 78
Clinical meta-analyses of targeted therapies in adenocarcinoma. 77
Mechanisms of resistance to chemotherapeutic and anti-angiogenic drugs as novel targets for pancreatic cancer therapy 77
Balancing activity and tolerability of neoadjuvant paclitaxel- and docetaxel-based chemotherapy for HER2-positive early stage breast cancer: Sensitivity analysis of randomized trials 77
Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft model. 76
Gefitinib ('Iressa, ZD1839') and a second generation antisense targeting murine double minute 2 (Mdm2) synergistically inhibit tumor growth and angiogenesis in hormone-refractory prostate cancer 76
8-Chloro-cAMP inhibits transforming growth factor alpha transformation of mammary epithelial cells by restoration of the normal mRNA patterns for cAMP-dependent protein kinase regulatory subunit isoforms which show disruption upon transformation. 76
Combination of a selective cyclooxygenase-2 inhibitor with EGFR tyrosine kinase inhibitor ZD1839 (‘Iressa’) and Protein Kinase A antisense causes a cooperative antitumor and antiangiogenic effect 75
ZD1839 (Iressa): preclinical studies and pharmacology. 75
Therapeutic integration of signal transduction targeting agents and conventional anti-cancer treatments. 75
Adjuvant treatment for resected renal cell carcinoma: are all strategies equally negative? Potential implications for trial design with targeted agents. 75
Toll-like receptor 9 agonist IMO cooperates with cetuximab in K-ras mutant colorectal and pancreatic cancers 74
Whole genomes redefine the mutational landscape of pancreatic cancer 74
The route to personalized medicine in bladder cancer: where do we stand? 74
Totale 9.599
Categoria #
all - tutte 79.536
article - articoli 72.053
book - libri 183
conference - conferenze 5.516
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 1.784
Totale 159.072

Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019143 0 0 0 0 0 0 0 0 0 0 0 143
2019/20202.775 444 49 27 229 308 261 337 189 155 298 217 261
2020/20213.001 292 599 130 371 474 236 33 152 143 76 307 188
2021/20222.735 204 783 17 211 94 46 41 175 109 61 199 795
2022/20235.509 474 505 555 863 538 1.411 55 324 586 36 118 44
2023/20242.345 104 203 180 202 382 381 51 232 45 125 353 87
Totale 24.237